# Interius BioTherapeutics

Source: https://onco.cc/companies/interius/  
OnCo record `interius` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Penn spin-out that dosed the first patient ever with a durable in vivo CAR gene therapy (INT2104, CD20) in the INVISE trial.

## Summary

INT2104 is an engineered lentiviral vector that generates CAR-T and CAR-NK cells against CD20 after a single IV infusion, without lymphodepletion. Phase 1 INVISE in relapsed/refractory B-cell malignancies started in Australia (2024-25); preclinical large-animal data showed B-cell depletion without CRS or neurotoxicity.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Tags: frontier
- HQ: Philadelphia, PA
- Type: cell-therapy
- Website: https://interiusbio.com

## Sources

- First patient dosed: https://interiusbio.com/press-release/interius-biotherapeutics-doses-first-patient-with-in-vivo-chimeric-antigen-receptor-car-gene-therapy-for-b-cell-malignancies/

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- targets: [CD20](https://onco.cc/targets/cd20/)
- institutions: [Abramson Cancer Center, University of Pennsylvania](https://onco.cc/institutions/penn-abramson/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)
- ideas: [In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma](https://onco.cc/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/), [In vivo CAR-T manufactured and priced like a generic biologic](https://onco.cc/ideas/idea-moon-in-vivo-cart-generic-price/)

---
JSON: https://onco.cc/api/v1/entities/interius.json